Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Erleada Clinical Study Report Is First Release In Drug Review Transparency Pilot

Executive Summary

US FDA publishes 1,000+ page CSR for J&J's prostate cancer drug, and eight more products will follow. But how useful will the extra information be?

You may also be interested in...



Clinical Study Report Release Could Compromise Patient Privacy, Groups Say

US FDA's plan to post CSRs may also inadvertently release confidential commercial information, agency is warned by industry groups.

US FDA May Scrap Clinical Study Report Disclosure For New Drug Approvals

The pilot project former Commissioner Gottlieb championed found only one sponsor interested in participating.

Janssen’s Apalutamide First To Gain Approval Under International Work Sharing Program

The ACSS Consortium’s work-sharing pilot for new drugs has yielded its first twin approval, for Janssen’s prostate cancer treatment, apalutamide.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS122779

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel